Clinical Validation

Our commitment to scientific rigor and transparent validation — from provenance hardening to IRB-approved clinical studies. Here's where we are and where we're going.

Our Commitment

Transparency is non-negotiable.

A Note on Scientific Honesty

Beverly Index is a novel technology built on established neuroscience. We are transparent about what has been validated and what remains to be proven. NOST's three premises are grounded in decades of peer-reviewed research — but the specific application of linguistic analysis as a proxy for neural oscillation measurement is our innovation, and it requires its own validation pathway.

We do not claim peer-reviewed validation for the Beverly Index scoring system at this stage. What we do claim is: rigorous provenance — every parameter in our system is traceable to published clinical research — and a clear, funded roadmap to independent clinical validation.

Validation Strategy

Three pillars of scientific credibility.

Pillar I

Provenance Hardening

Every constant, weight, threshold, and classification in the NOUS platform is traceable to published clinical literature. Zero arbitrary parameters.

  • 12-vector affinity matrix grounded in DSM-5/HiTOP
  • R2X sub-weights traced to NLP-EEG correspondence research
  • Severity thresholds aligned to CGI-S clinical scales
  • Treatment protocols sourced from APA/NICE/Cochrane
  • Full provenance audit completed March 2026
Pillar II

Internal Validation

Systematic internal testing across diverse narrative scenarios, demographic profiles, and clinical presentations to ensure consistency and reliability.

  • Expanded corpus testing (30+ narrative scenarios)
  • Cross-cultural calibration via LOGOS (9 populations)
  • Conflict resolution between scoring components
  • Edge case handling and boundary condition testing
  • Automated regression testing (2,197+ tests passing)
Pillar III

External Clinical Validation

The ultimate standard — independent IRB-approved studies comparing Beverly Index results against established clinical instruments and expert assessments.

  • IRB protocol development (in progress)
  • Multi-site clinical partnerships
  • Concordance studies against DSM-5 structured interviews
  • Peer-reviewed publication strategy
  • Grant-funded research partnerships
Validation Roadmap

The path to clinical proof.

Q4 2025 – Q1 2026
Provenance Hardening
Full system audit across all scoring components. Elimination of demo-tagged parameters. Every constant grounded in published research. Completed March 2026 with zero DEMO-tagged artifacts remaining in the production system.
Completed
Q1 2026
Platform Deployment & Internal Testing
NOUS platform deployed to production (Render.com). Three pathway-specific dashboards (CI, CSAA, VOCA) operational. Expanded corpus testing with 30+ diverse narrative scenarios. Full test suite passing.
Active
Q2 2026
Grant-Funded Research Initiation
RWJF grant submission (deadline April 13, 2026) for LOGOS cross-cultural calibration study — "Hearing What Has Been Silenced." Partnership development with academic institutions for IRB-approved protocols.
In Progress
Q3–Q4 2026
IRB Protocol & Clinical Partnerships
IRB submission for multi-site validation study. Partnership establishment with clinical research sites. Study design: Beverly Index concordance against structured clinical interviews (SCID-5), validated symptom measures (PHQ-9, GAD-7, PCL-5), and expert clinical judgment.
Upcoming
2027
Clinical Validation Studies
Data collection across multiple clinical sites. Target population: diverse demographic and diagnostic profiles. Outcome measures: sensitivity, specificity, concordance, test-retest reliability, inter-rater agreement.
Planned
2027–2028
Peer-Reviewed Publication
Submission to peer-reviewed clinical journals. Three-tier publication strategy: foundational theory papers, clinical validation results, and cross-cultural calibration findings. Patent attorney review prior to all publications.
Planned
Provenance Audit

Every parameter accounted for.

In March 2026, we completed a comprehensive system audit — scanning every constant, weight, and threshold across the entire NOUS platform to ensure full traceability to published clinical research.

Audit Results

The system-wide provenance audit examined all scoring parameters across 68 files in the NOUS codebase.

892 Total constants audited across 68 files
0 DEMO-tagged artifacts remaining (down from 40)
4 Governing document divergences identified and resolved

Provenance Sources

All scoring parameters trace to one or more of these evidence categories.

DSM-5 Diagnostic criteria alignment (via HiTOP dimensional model)
CGI-S Severity thresholds (Clinical Global Impressions Scale)
APA Treatment protocols (APA, NICE, Cochrane guidelines)
EEG Oscillation weights traced to NLP-EEG correspondence studies

RWJF Grant Application

Beverly Index LLC has submitted a grant application to the Robert Wood Johnson Foundation, anchored in the LOGOS cross-cultural calibration system — "Hearing What Has Been Silenced."

The proposed research focuses on validating LOGOS cultural calibration across diverse populations, drawing on Italy's Basaglia/Democratic Psychiatry movement, Brazil's CAPS community mental health model, and New Zealand's Te Whare Tapa Wha indigenous health framework.

Foundation
Robert Wood Johnson Foundation
Focus Area
LOGOS Cross-Cultural Calibration
Application Deadline
April 13, 2026
Proposal Title
"Hearing What Has Been Silenced"

Want to collaborate?

We're seeking clinical research partners, academic institutions, and grant-funded collaborators.

Contact Our Research Team Review NOST Framework